Pahnwat Tonya Taweesedt1 and Salim Surani2*
1Fellow, Pulmonary Medicine, Corpus Christi Medical Center, Texas, USA
2Adjunct Clinical Professor, Texas A&M University, Texas, USA
*Corresponding Author: Salim Surani, Adjunct Clinical Professor, Texas A&M University, Texas, USA.
Received: August 20, 2020; Published: August 31, 2020
Gastrointestinal (GI) bleeding is one of the causes leading to death worldwide. Approximately 47/100,000 for upper gastrointestinal bleeding (UGIB) and 33/100,000 for lower gastrointestinal bleeding (LGIB) . Intravenous fluid, blood products, medications, surgical, and endoscopy procedure have been used as the treatment for GI bleeding. Tranexamic acid (TXA) has been proposed as one of the medications that reduced mortality in GI bleeding . It is an anti-fibrinolytic agent that reduces bleeding in many clinical conditions especially in trauma settings . However, the current guidelines do not recommend tranexamic acid for UGIB or LGIB treatment [4,5].
Citation: Pahnwat Tonya Taweesedt and Salim Surani. “Early Use of Tranexamic Acid in Gastrointestinal Bleed". Acta Scientific Medical Sciences 4.10 (2020): 01-02.
Copyright: © 2020 Pahnwat Tonya Taweesedt and Salim Surani. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.